Intelligent Bio Solutions (INBS) Stock Overview
A medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
INBS Community Fair Values
Create NarrativeSee what 68 others think this stock is worth. Follow their fair value or set your own to get alerts.
Intelligent Bio Solutions Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.31 |
| 52 Week High | US$27.50 |
| 52 Week Low | US$4.03 |
| Beta | 4.46 |
| 1 Month Change | 93.30% |
| 3 Month Change | 33.74% |
| 1 Year Change | 1.49% |
| 3 Year Change | -97.87% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
The Future of Drug Testing? Fingerprint Tech From Intelligent Bio Solutions (NASDAQ:INBS) Shows Serious Promise
Jun 18
GBS acquires Intelligent Fingerprinting in all-stock deal
Oct 04GBS GAAP EPS of -$0.57, revenue of $0.44M
Aug 31GBS Inc.: Can Its Technology Come Through?
Aug 31GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing
Aug 09Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?
Jul 29Shareholder Returns
| INBS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 50.2% | 3.2% | 1.5% |
| 1Y | 1.5% | 4.5% | 17.3% |
Return vs Industry: INBS underperformed the US Medical Equipment industry which returned 4.7% over the past year.
Return vs Market: INBS underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| INBS volatility | |
|---|---|
| INBS Average Weekly Movement | 42.0% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INBS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INBS's weekly volatility has increased from 24% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 54 | Harry Simeonidis | ibs.inc |
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.
Intelligent Bio Solutions Inc. Fundamentals Summary
| INBS fundamental statistics | |
|---|---|
| Market cap | US$11.19m |
| Earnings (TTM) | -US$10.87m |
| Revenue (TTM) | US$3.29m |
Is INBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBS income statement (TTM) | |
|---|---|
| Revenue | US$3.29m |
| Cost of Revenue | US$1.87m |
| Gross Profit | US$1.42m |
| Other Expenses | US$12.28m |
| Earnings | -US$10.87m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.50 |
| Gross Margin | 43.08% |
| Net Profit Margin | -330.07% |
| Debt/Equity Ratio | 4.1% |
How did INBS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 12:58 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intelligent Bio Solutions Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Cohen | Ladenburg Thalmann & Company |
| John Vandermosten | Zacks Small-Cap Research |